The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CheckMate-032: Phase I/II, open-label study of safety and activity of nivolumab (nivo) alone or with ipilimumab (ipi) in advanced and metastatic (A/M) gastric cancer (GC).
 
Yelena Yuriy Janjigian
Consulting or Advisory Role - Lilly
Research Funding - Bayer; Boehringer Ingelheim
 
Johanna C. Bendell
No Relationships to Disclose
 
Emiliano Calvo
Consulting or Advisory Role - Astellas Pharma; GlaxoSmithKline; Lilly/ImClone; Nanobiotix; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Novartis
Research Funding - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Eisai; Janssen Oncology; Lilly; Merck; Millennium; Nektar; Novartis; OncoMed; Pfizer; PharmaMar; PsiOxus Therapeutics; Puma Biotechnology; Roche/Genentech; Sanofi; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Lilly; Novartis; PsiOxus Therapeutics
Other Relationship - Pierre Fabre
 
Joseph W. Kim
Consulting or Advisory Role - Dendreon
Research Funding - Immune Design
 
Paolo Antonio Ascierto
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; MSD; Novartis; Roche/Genentech; Ventana Medical Systems
Research Funding - Bristol-Myers Squibb; Roche/Genentech; Ventana Medical Systems
 
Padmanee Sharma
Leadership - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Neon Therapeutics (I); SAB-Pharma; SAB-Pharma (I)
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline
Research Funding - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Patrick Alexander Ott
Consulting or Advisory Role - Alexion Pharmaceuticals; Amgen; Bristol-Myers Squibb
Research Funding - ARMO BioSciences; AstraZeneca; Bristol-Myers Squibb; Merck
 
Petri Bono
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Orion
 
Dirk Jaeger
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Roche
 
T.R. Jeffry Evans
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - Baxter (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Karus Therapeutics (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca (Inst); Basilea (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); e-Therapeutics (Inst); GlaxoSmithKline (Inst); Immunocore (Inst); Merck (Inst); Roche (Inst); TC Biopharm (Inst); Vertex (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene
 
Filippo G. De Braud
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Fondazione IRCCS Istituto Tumori Milano
 
Ian Chau
Honoraria - Amgen; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Lilly; Merck Serono; MSD; Sanofi
Research Funding - Janssen-Cilag; Merck Serono; Roche; Sanofi
 
Marina Tschaika
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Christopher T. Harbison
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Chen-Sheng Lin
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Dung T. Le
Research Funding - Aduro Biotech; Bristol-Myers Squibb; Merck